SAAM is treated by stopping the offending<unk>  medication and taking immunosuppressive medications. In rare cases, affected people spontaneously improve after just stopping the implicated<unk> . However, most cases mandate the use of immunosuppressive medication. Corticosteroids are considered first-line treatment. Prednisone dosed at 1 milligram/kilogram of body weight daily is generally recommended. Corticosteroid therapy alone may be reasonable in cases of mild muscular weakness. More severe cases require the use of combined methotrexate, azathioprine, or mycophenolate with corticosteroids. Severe cases of SAAM may fail to respond to 8-12 weeks of combination therapy. Rituximab or intravenous immunoglobulin are recommended as add-on therapy in such cases. Intravenous immunoglobulin is an appropriate first-line therapy in select individuals. Suitable candidates for first-line intravenous immunoglobulin include people who have diabetes mellitus or who wish to avoid corticosteroid therapy.
Statin-associated autoimmune myopathy
Desmin-related myofibrillar myopathy
Acquired non-inflammatory myopathy
Dermatopolymyositis
Inclusion body myositis
Scleromyositis
Dermatomyositis
Hereditary inclusion body myopathy